OPtimising Treatment with Tumour necrosis factor (TNF) Inhibitors in Rheumatoid Arthritis: is dose tapering practical in good responders? A 'proof of principle' and exploratory trial

King's College London (KCL) (UK)0 个研究点目标入组 99 人开始时间: 2011年5月25日最近更新: 2018年7月2日

适应症

试验速览

•1. RA by American College of Rheumatology and EULAR criteria
•2. Etanercept or adalimumab treatment for at least 6 months (a break of up to 4 consecutive weeks is permitted)
•3. Taking at least one DMARD
•4. Stable clinical response for at least 3 months (one DAS28 score of 3.2 or less; no increase in DAS28 greater than 0.6)
•5. Patient considers he or she has achieved a suitable response to TNF inhibitors
•6. Supervising rheumatologist considers further improvements are unlikely on the patients current treatment regimen
•7. At least 18 years of age, either sex
•8. Willing and able to give informed consent

•1. Serious concurrent illness (e.g. terminal cancer)
•2. Prednisolone at more than 10mg daily (for doses > 10mg daily, a 4 week washout period is required)
•3. Recently received intramuscular (IM)/intra-areterial (IA) steroids (12 weeks washout required)
•4. Pregnancy, breast-feeding or women of child-bearing potential not using adequate contraception

发起方

King's College London (KCL) (UK)